Development of a new hydrogen peroxide–based vaccine platform

Nat Med. 2012 Jun;18(6):974-9. doi: 10.1038/nm.2763.

Abstract

Safe and effective vaccines are crucial for maintaining public health and reducing the global burden of infectious disease. Here we introduce a new vaccine platform that uses hydrogen peroxide (H(2)O(2)) to inactivate viruses for vaccine production. H(2)O(2) rapidly inactivates both RNA and DNA viruses with minimal damage to antigenic structure or immunogenicity and is a highly effective method when compared with conventional vaccine inactivation approaches such as formaldehyde or β-propiolactone. Mice immunized with H(2)O(2)-inactivated lymphocytic choriomeningitis virus (LCMV) generated cytolytic, multifunctional virus-specific CD8(+) T cells that conferred protection against chronic LCMV infection. Likewise, mice vaccinated with H(2)O(2)-inactivated vaccinia virus or H(2)O(2)-inactivated West Nile virus showed high virus-specific neutralizing antibody titers and were fully protected against lethal challenge. Together, these studies demonstrate that H(2)O(2)-based vaccines are highly immunogenic, provide protection against a range of viral pathogens in mice and represent a promising new approach to future vaccine development.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • CD8-Positive T-Lymphocytes / immunology
  • Female
  • Humans
  • Hydrogen Peroxide / pharmacology*
  • Lymphocytic choriomeningitis virus / immunology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Middle Aged
  • Vaccination
  • Vaccines, Inactivated / immunology
  • Viral Vaccines / immunology*
  • West Nile Fever / immunology
  • West Nile virus / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Vaccines, Inactivated
  • Viral Vaccines
  • Hydrogen Peroxide